Matulane (procarbazine hydrochloride)

P2, N=65, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Not yet recruiting --> Recruiting

P1/2, N=118, Active, not recruiting, Institut Curie | Trial primary completion date: Aug 2025 --> Feb 2035

P2, N=65, Not yet recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

P1, N=20, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Recruiting --> Active, not recruiting

After three cycles of procarbazine, lomustine, and vincristine chemotherapy, the residual tumor stabilized for 3 years...Recurrent anaplastic oligodendroglioma was confirmed, and adjuvant proton beam therapy and temozolomide chemotherapy were initiated...Continued regression led to complete remission-confirmed via MRI at the 15-month follow-up and sustained for 4.7 years. The patient's peripheral blood monocyte profiles and immune-associated cytokine analysis indicated T-cell activation following WT-1 sensitization.

In this patient, CEH could have resulted from VEGFR-1 expression due to GKRS. For a patient with slow lesion growth following GKRS for PCNSL, surgical removal should be considered, taking into account the possibility of CEH along with recurrence and radiation necrosis. https://thejns.org/doi/10.3171/CASE258.

P1/2, N=118, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | Trial completion date: Feb 2035 --> Aug 2035 | Trial primary completion date: Feb 2025 --> Aug 2025

After five cycles of R-MPV (rituximab, methotrexate, procarbazine, vincristine) therapy and three cycles of R-ESHAP (rituximab, etoposide, cytarabine, cisplatin, methylprednisolone) therapy, the patient received autologous hematopoietic stem cell transplantation using R-MEAM (rituximab, ranimustine, etoposide, cytarabine, melphalan) regimen after bridging therapy with ibrutinib. He did not relapse within 3 years of transplantation. To the best of our knowledge, this is the first case report of DLBCL and MCL coexistence.

P2, N=72, Completed, International Extranodal Lymphoma Study Group (IELSG) | Recruiting --> Completed | N=208 --> 72

P3, N=406, Recruiting, University Hospital Heidelberg | Trial completion date: Mar 2029 --> Mar 2031 | Trial primary completion date: Mar 2029 --> Mar 2031

Procarbazine induces a higher mutation burden and novel mutational signatures in patients with Hodgkin lymphoma treated with eBEACOPP and their germline DNA, raising concerns for the genomic health of survivors of Hodgkin lymphoma and hereditary consequences for their offspring. However, replacing procarbazine with dacarbazine appears to mitigate gonadal and stem-cell toxicity while maintaining similar clinical efficacy.

Despite advances in treatment, the median survival of patients with GBM is only 15 months. This case highlights the potential of immunotherapy with PD-L1 checkpoint inhibition in improving outcomes for LFS-associated GBM patients. https://thejns.org/doi/10.3171/CASE24539.